DOCSLIB.ORG

L:\0901 with Peru\0901PHARMAPPX.Wpd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6 ACRIDOREX 47487-22-9 ACARBOSE 56180-94-0 ACRIFLAVINIUM CHLORIDE 8063-24-9 ACEBROCHOL 514-50-1 ACRIHELLIN 67696-82-6 ACEBURIC ACID 26976-72-7 ACRISORCIN 7527-91-5 ACEBUTOLOL 37517-30-9 ACRIVASTINE 87848-99-5 ACECAINIDE 32795-44-1 ACROCINONIDE 28971-58-6 ACECARBROMAL 77-66-7 ACRONINE 7008-42-6 ACECLIDINE 827-61-2 ACTAGARDIN ACECLOFENAC 89796-99-6 ACTAPLANIN 37305-75-2 ACEDAPSONE 77-46-3 ACTARIT 18699-02-0 ACEDIASULFONE SODIUM 127-60-6 ACTINOQUINOL 15301-40-3 ACEDOBEN 556-08-1 ACTISOMIDE 96914-39-5 ACEFLURANOL 80595-73-9 ACTODIGIN 36983-69-4 ACEFURTIAMINE 10072-48-7 ADAFENOXATE 82168-26-1 ACEFYLLINE PIPERAZINE 18428-63-2 ADALIMUMAB 331731-18-1 ACEFYLLINE CLOFIBROL 70788-27-1 ADAMEXINE 54785-02-3 ACEGLATONE 642-83-1 ADAPALENE 106685-40-9 ACEGLUTAMIDE 2490-97-3 ADAPROLOL 101479-70-3 ACEMANNAN 110042-95-0 ADARGILEUKIN ALFA 250710-65-7 ACEMETACIN 53164-05-9 ADATANSERIN 127266-56-2 ACENEURAMIC ACID 131-48-6 ADECATUMUMAB 503605-66-1 ACENOCOUMAROL 152-72-7 ADEFOVIR 106941-25-7 ACEPERONE 807-31-8 ADEKALANT 227940-00-3 ACEPROMAZINE 61-00-7 ADELMIDROL 1675-66-7 ACEPROMETAZINE 13461-01-3 ADEMETIONINE 17176-17-9 ACEQUINOLINE 42465-20-3 ADENOSINE PHOSPHATE 61-19-8 ACESULFAME 33665-90-6 ADIBENDAN 100510-33-6 ACETAMINOSALOL 118-57-0 ADICILLIN 525-94-0 ACETARSOL 97-44-9 ADIMOLOL 78459-19-5 ACETAZOLAMIDE 59-66-5 ADINAZOLAM 37115-32-5 ACETERGAMINE 3031-48-9 ADIPHENINE 64-95-9 ACETIAMINE 299-89-8 ADIPIODONE 606-17-7 ACETIROMATE 2260-08-4 ADITEREN 56066-19-4 ACETOHEXAMIDE 968-81-0 ADITOPRIM 56066-63-8 ACETOHYDROXAMIC ACID 546-88-3 ADOSOPINE 88124-26-9 ACETOPHENAZINE 2751-68-0 ADOZELESIN 110314-48-2 ACETORPHINE 25333-77-1 ADRAFINIL 63547-13-7 ACETRYPTINE 3551-18-6 ADRENALONE 99-45-6 ACETYLCHOLINE CHLORIDE 60-31-1 ADROGOLIDE 171752-56-0 ACETYLCYSTEINE 616-91-1 AFALANINE 2901-75-9 ACETYLDIGITOXIN 1111-39-3 AFELETECAN 215604-75-4 ACETYLLEUCINE 99-15-0 AFELIMOMAB 156227-98-4 ACETYLMETHADOL 509-74-0 AFLOQUALONE 56287-74-2 ACEVALTRATE 25161-41-5 AFOVIRSEN 151356-08-0 Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes 3 AFUROLOL 65776-67-2 ALLYLESTRENOL 432-60-0 AGALSIDASE ALFA 104138-64-9 ALLYLPRODINE 25384-17-2 AGALSIDASE BETA 104138-64-9 ALLYLTHIOUREA 109-57-9 AGANODINE 86696-87-9 ALMADRATE SULFATE 60239-66-9 AGLEPRISTONE 124478-60-0 ALMAGATE 66827-12-1 AGOMELATINE 138112-76-2 ALMAGODRATE 103371-13-8 AKLOMIDE 3011-89-0 ALMASILATE 71205-22-6 ALACEPRIL 74258-86-9 ALMECILLIN 87-09-2 ALAFOSFALIN 60668-24-8 ALMESTRONE 10448-96-1 ALAGEBRIUM CHLORIDE 341028-37-3 ALMINOPROFEN 39718-89-3 ALAMIFOVIR 193681-12-8 ALMITRINE 27469-53-0 ALANINE 56-41-7 ALMOKALANT 123955-10-2 ALANOSINE 5854-93-3 ALMOTRIPTAN 154323-57-6 ALAPROCLATE 60719-82-6 ALMOXATONE 84145-89-1 ALATROFLOXACIN 157182-32-6 ALMURTIDE 61136-12-7 ALAZANINE TRICLOFENATE 5779-59-9 ALNESPIRONE 138298-79-0 ALBACONAZOLE 187949-02-6 ALNIDITAN 152317-89-0 ALBENDAZOLE 54965-21-8 ALONACIC 105292-70-4 ALBENDAZOLE OXIDE 54029-12-8 ALONIMID 2897-83-8 ALBIFYLLINE 107767-55-5 ALORACETAM 119610-26-3 ALBUTOIN 830-89-7 ALOSETRON 122852-42-0 ALCLOFENAC 22131-79-9 ALOVUDINE 25526-93-6 ALCLOMETASONE 67452-97-5 ALOXIPRIN 9014-67-9 ALCLOXA 1317-25-5 ALOXISTATIN 88321-09-9 ALCURONIUM CHLORIDE 15180-03-7 ALOZAFONE 65899-72-1 ALDESULFONE SODIUM 144-75-2 ALPERTINE 27076-46-6 ALDIOXA 5579-81-7 ALPHACETYLMETHADOL 17199-58-5 ALDOSTERONE 52-39-1 ALPHAMEPRODINE 468-51-9 ALEFACEPT 222535-22-0 ALPHAMETHADOL 17199-54-1 ALEMCINAL 150785-53-8 ALPHAPRODINE 77-20-3 ALEMTUZUMAB 216503-57-0 ALPIDEM 82626-01-5 ALENDRONIC ACID 66376-36-1 ALPIROPRIDE 81982-32-3 ALENTEMOL 112891-97-1 ALPRAFENONE 124316-02-5 ALEPRIDE 66564-15-6 ALPRAZOLAM 28981-97-7 ALESTRAMUSTINE 139402-18-9 ALPRENOLOL 13655-52-2 ALEXIDINE 22573-93-9 ALPROSTADIL 745-65-3 ALEXITOL SODIUM 66813-51-2 ALRESTATIN 51411-04-2 ALFACALCIDOL 41294-56-8 ALSACTIDE 34765-96-3 ALFADEX 10016-20-3 ALTANSERIN 76330-71-7 ALFADOLONE 14107-37-0 ALTAPIZONE 93277-96-4 ALFAPROSTOL 74176-31-1 ALTECONAZOLE 93479-96-0 ALFATRADIOL 57-91-0 ALTEPLASE 105857-23-6 ALFAXALONE 23930-19-0 ALTINICLINE 179120-92-4 ALFENTANIL 71195-58-9 ALTIZIDE 5588-16-9 ALFETAMINE 4255-23-6 ALTOQUALINE 121029-11-6 ALFIMEPRASE 259074-76-5 ALTRENOGEST 850-52-2 ALFUZOSIN 81403-80-7 ALTRETAMINE 645-05-6 ALGELDRATE 1330-44-5 ALTUMOMAB 156586-92-4 ALGESTONE 595-77-7 ALUMINIUM CLOFIBRATE 24818-79-9 ALGLUCERASE 143003-46-7 ALUSULF 61115-28-4 ALGLUCOSIDASE ALFA 420784-05-0 ALVAMELINE 120241-31-8 ALIBENDOL 26750-81-2 ALVERINE 150-59-4 ALICAFORSEN 185229-68-9 ALVIMOPAN 156053-89-3 ALICONAZOLE 63824-12-4 ALVIRCEPT SUDOTOX 137487-62-8 ALIFEDRINE 78756-61-3 ALVOCIDIB 146426-40-6 ALIFLURANE 56689-41-9 AMADINONE 30781-27-2 ALILUSEM 144506-11-6 AMAFOLONE 50588-47-1 ALIMADOL 52742-40-2 AMANOZINE 537-17-7 ALIMEMAZINE 84-96-8 AMANTADINE 768-94-5 ALINASTINE 154541-72-7 AMANTANIUM BROMIDE 58158-77-3 ALINIDINE 33178-86-8 AMANTOCILLIN 10004-67-8 ALIPAMIDE 3184-59-6 AMBAMUSTINE 85754-59-2 ALISKIREN 173334-57-1 AMBASILIDE 83991-25-7 ALITRETINOIN 5300-03-8 AMBAZONE 539-21-9 ALIZAPRIDE 59338-93-1 AMBENONIUM CHLORIDE 115-79-7 ALLETORPHINE 23758-80-7 AMBENOXAN 2455-84-7 ALLOBARBITAL 52-43-7 AMBICROMIL 58805-38-2 ALLOCLAMIDE 5486-77-1 AMBOMYCIN 1402-81-9 ALLOCUPREIDE SODIUM 5965-40-2 AMBRISENTAN 177036-94-1 ALLOMETHADIONE 526-35-2 AMBROXOL 18683-91-5 ALLOPURINOL 315-30-0 AMBRUTICIN 58857-02-6 Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 AMBUCAINE 119-29-9 AMITEROL 54063-25-1 AMBUCETAMIDE 519-88-0 AMITIVIR 111393-84-1 AMBUSIDE 3754-19-6 AMITRAZ 33089-61-1 AMCINAFAL 3924-70-7 AMITRIPTYLINE 50-48-6 AMCINAFIDE 7332-27-6 AMITRIPTYLINOXIDE 4317-14-0 AMCINONIDE 51022-69-6 AMIXETRINE 24622-72-8 AMDOXOVIR 145514-04-1 AMLEXANOX 68302-57-8 AMEBUCORT 83625-35-8 AMLINTIDE 122384-88-7 AMEDALIN 22136-26-1 AMLODIPINE 88150-42-9 AMEDIPLASE 151912-11-7 AMOBARBITAL 57-43-2 AMELOMETASONE 123013-22-9 AMOCARZINE 36590-19-9 AMELTOLIDE 787-93-9 AMODIAQUINE 86-42-0 AMELUBANT 346735-24-8 AMOGASTRIN 16870-37-4 AMESERGIDE 121588-75-8 AMOLANONE 76-65-3 AMETANTRONE 64862-96-0 AMONAFIDE 69408-81-7 AMEZEPINE 60575-32-8 AMOPROXAN 22661-76-3 AMEZINIUM METILSULFATE 30578-37-1 AMOPYROQUINE 550-81-2 AMFEBUTAMONE 34911-55-2 AMOROLFINE 78613-35-1 AMFECLORAL 5581-35-1 AMOSCANATE 26328-53-0 AMFENAC 51579-82-9 AMOSULALOL 85320-68-9 AMFEPENTOREX 15686-27-8 AMOTOSALEN 161262-29-9 AMFEPRAMONE 90-84-6 AMOXAPINE 14028-44-5 AMFETAMINE 300-62-9 AMOXECAINE 553-65-1 AMFETAMINIL 17590-01-1 AMOXICILLIN 26787-78-0 AMFLUTIZOLE 82114-19-0 AMOXYDRAMINE CAMSILATE 15350-99-9 AMFOMYCIN 1402-82-0 AMPEROZIDE 75558-90-6 AMFONELIC ACID 15180-02-6 AMPHENIDONE 134-37-2 AMICARBALIDE 3459-96-9 AMPHOTALIDE 1673-06-9 AMICIBONE 23271-63-8 AMPHOTERICIN B 1397-89-3 AMICYCLINE 5874-95-3 AMPICILLIN 69-53-4 AMIDANTEL 49745-00-8 AMPIROXICAM 99464-64-9 AMIDAPSONE 3569-77-5 AMPRENAVIR 161814-49-9 AMIDEFRINE MESILATE 1421-68-7 AMPROLIUM 121-25-5 AMIFLAMINE 77518-07-1 AMPYRIMINE 5587-93-9 AMIFLOVERINE 54063-24-0 AMPYZINE 5214-29-9 AMIFLOXACIN 86393-37-5 AMQUINATE 17230-85-2 AMIFOSTINE 20537-88-6 AMRINONE 60719-84-8 AMIGLUMIDE 119363-62-1 AMRUBICIN 110267-81-7 AMIKACIN 37517-28-5 AMSACRINE 51264-14-3 AMIKHELLINE 4439-67-2 AMTOLMETIN GUACIL 87344-06-7 AMILORIDE 2609-46-3 AMYLMETACRESOL 1300-94-3 AMINDOCATE 31386-24-0 ANAGESTONE 2740-52-5 AMINEPTINE 57574-09-1 ANAGRELIDE 68475-42-3 AMINITROZOLE 140-40-9 ANAKINRA 143090-92-0 AMINOACRIDINE 90-45-9 ANARITIDE 95896-08-5 AMINOCAPROIC ACID 60-32-2 ANASTROZOLE 120511-73-1 AMINOETHYL NITRATE 646-02-6 ANATIBANT 209733-45-9 AMINOGLUTETHIMIDE 125-84-8 ANATUMOMAB MAFENATOX AMINOMETRADINE 642-44-4 ANAXIRONE 77658-97-0 AMINOPHENAZONE CYCLAMATE 747-30-8 ANAZOCINE 15378-99-1 AMINOPHENAZONE 58-15-1 ANAZOLENE SODIUM 3861-73-2 AMINOPHYLLINE 317-34-0 ANCAROLOL 75748-50-4 AMINOPROMAZINE 58-37-7 ANCESTIM 163545-26-4 AMINOPTERIN SODIUM 58602-66-7 ANCITABINE 31698-14-3 AMINOQUINOL 10023-54-8 ANCRIVIROC 370893-06-4 AMINOQUINURIDE 3811-56-1 ANCROD 9046-56-4 AMINOREX 2207-50-3 ANDOLAST 132640-22-3 AMINOTHIAZOLE 96-50-4 ANDROSTANOLONE 521-18-6 AMINOXYTRIPHENE 5585-64-8 ANECORTAVE 7753-60-8 AMIODARONE 1951-25-3 ANGIOTENSIN II 4474-91-3 AMIPERONE 1580-71-8 ANGIOTENSINAMIDE 53-73-6 AMIPHENAZOLE 490-55-1 ANIDOXIME 34297-34-2 AMIPIZONE 69635-63-8 ANIDULAFUNGIN 166663-25-8 AMIPRILOSE 56824-20-5 ANILAMATE 5591-49-1 AMIQUINSIN 13425-92-8 ANILERIDINE 144-14-9 AMISOMETRADINE 550-28-7 ANILOPAM 53716-46-4 AMISULPRIDE 71675-85-9 ANIPAMIL 83200-10-6 Harmonized Tariff Schedule of the United States (2009) (Rev.
Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of

    Antiseptics and Disinfectants for the Treatment Of

    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
  • Commission Decision of 8 February 2010 Concerning The

    Commission Decision of 8 February 2010 Concerning The

    L 36/36 EN Official Journal of the European Union 9.2.2010 COMMISSION DECISION of 8 February 2010 concerning the non-inclusion of certain substances in Annex I, IA or IB to Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (notified under document C(2010) 751) (Text with EEA relevance) (2010/72/EU) THE EUROPEAN COMMISSION, concerned should therefore not be included in Annex I, IA or IB to Directive 98/8/EC. Having regard to the Treaty on the Functioning of the European Union, (6) In the interest of legal certainty, biocidal products Having regard to Directive 98/8/EC of the European Parliament containing active substances for the product-types and of the Council of 16 February 1998 concerning the placing indicated in the Annex to this Decision should no of biocidal products on the market ( 1), and in particular the longer be placed on the market, with effect from a second subparagraph of Article 16(2) thereof, specific date. Whereas: (7) The measures provided for in this Decision are in accordance with the opinion of the Standing (1) Commission Regulation (EC) No 1451/2007 of Committee on Biocidal Products, 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive HAS ADOPTED THIS DECISION: 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the Article 1 market ( 2) establishes a list of active substances to be assessed, with a view to their possible inclusion in The substances indicated in the Annex to this Decision shall not Annex I, IA or IB to Directive 98/8/EC.
  • Drug Class Review Beta Adrenergic Blockers

    Drug Class Review Beta Adrenergic Blockers

    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • HIV-Infected Patients

    HIV-Infected Patients

    New Drugs for the Treatment-Experienced Patient Joseph Eron, md Associate Professor of Medicine and Director, Clinical Core unc Center for aids Research, University of North Carolina at Chapel Hill Summary by Tim Horn Edited by Jay Dobkin, md; Michael Saag, md reatment options for antiretro- humans by adenosine deaminase into D- Deeks and his colleagues in 1998 demon- viral-experienced patients leave a dioxolane guanine (dxg), a metabolite that strated a 1 log reduction in hiv-rna in hiv- lot to be desired. According to Dr. has potent activity against hiv and hbv. infected patients—more than 50% of whom Joe Eron, patients who have treat- According to in vitro data presented at were treatment-experienced—who received ment experience in all three classes the 3rd International Workshop on hiv tenofovir df 300 mg once daily as of currently available antiretrovi- Drug Resistance and Treatment Strategies, monotherapy for 28 days (Deeks, 1998). Trals have, at best, a 30% chance of re- held in June 1999, dapd was found to in- According to in vitro data presented by ducing their viral load to levels below 400 hibit wild-type and mutant isolates resistant Gilead’s Dr. Michael Miller at the recent copies/mL upon initiating a salvage regi- to azt (Retrovir) and 3TC (Borroto-Esoda, 4th International Resistance Workshop, the men. Cross-resistance within each class of 1999). The drug was also reported to be ac- resistance pattern for tenofovir df is simi- drugs, particularly the protease inhibitors tive against strains collected from patients lar to that of its chemical predecessor adefo- (pis) and non-nucleoside reverse tran- who have failed various nrti and nnrti vir, a compound no longer in development scriptase inhibitors (nnrtis), essentially combination therapies, including those for the treatment of hiv (Miller, 2000).
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies

    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.